Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation

NCT ID: NCT03683030

Last Updated: 2025-10-17

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

397 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-10-22

Study Completion Date

2022-02-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this clinical investigation is to demonstrate safety and effectiveness of the Multi-Electrode RF Balloon catheter for the treatment of drug refractory symptomatic paroxysmal atrial fibrillation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The STELLAR study is a pivotal, prospective, multicenter, single-arm, clinical evaluation of the Multi-Electrode RF Balloon catheter. The study will evaluate the safety and effectiveness of the Multi-Electrode RF Balloon catheter used for ablation in patients with paroxysmal atrial fibrillation (PAF).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Group

Ablation using Multi-electrode Radiofrequency (RF) Balloon Catheter (HELIOSTAR).

Group Type EXPERIMENTAL

Multi-Electrode RF Balloon Catheter

Intervention Type DEVICE

Multi-Electrode RF Balloon Catheter will be inserted

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Multi-Electrode RF Balloon Catheter

Multi-Electrode RF Balloon Catheter will be inserted

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

HELIOSTAR

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with Symptomatic Paroxysmal Atrial Fibrillation.

1. At least two symptomatic AF episodes within last six months from enrollment.
2. At least one ectrocardiographically documented AF episode within twelve (12) months prior to enrollment.
* Failed at least one Class I or Class III antiarrhythmic drug.
* Age 18 -75 years.

Exclusion Criteria

* AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.
* Previous surgical or catheter ablation for AF.
* Previously diagnosed with persistent or long-standing persistent AF and/or Continuous AF \> 7 days.
* Any percutaneous coronary intervention within the past 2 months.
* Valve repair or replacement or presence of a prosthetic valve.
* Any carotid stenting or endarterectomy within the past 6 months.
* Coronary artery bypass grafting, cardiac surgery, or valvular cardiac surgical procedure within the past 6 months.
* Documented left atrium (LA) thrombus within 1 day prior to the index procedure.
* LA antero posterior diameter \> 50 mm.
* Left Ventricular Ejection Fraction (LVEF) \< 40%.
* Contraindication to anticoagulation (e.g., heparin).
* Myocardial infarction within the past 2 months.
* Documented thromboembolic event (including transient ischemic attack) within the past 12 months.
* Uncontrolled heart failure or New York Heart Association (NYHA) function class III or IV.
* Awaiting cardiac transplantation or other cardiac surgery within the next 12 months.
* Presence of implanted pacemaker or implantable cardioverter defibrillator (ICD).
* Women who are pregnant, lactating, or who are of child bearing age and plan on becoming pregnant during the course of the clinical investigation.
* Life expectancy or other disease processes likely to limit survival to less than 12 months.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biosense Webster, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Andrea Natale, MD

Role: PRINCIPAL_INVESTIGATOR

Texas Cardiac Arrhythmia Research Foundation

Srinivas Dukkipati, MD

Role: PRINCIPAL_INVESTIGATOR

Icahn School of Medicine at Mount Sinai

Moussa Mansour, MD

Role: PRINCIPAL_INVESTIGATOR

Massachusetts General Hospital

J. Brian Deville, MD

Role: PRINCIPAL_INVESTIGATOR

Baylor Research Institute

Sandeep Goysl, MD

Role: PRINCIPAL_INVESTIGATOR

Piedmont Hospital

Arash Aryana, MD

Role: PRINCIPAL_INVESTIGATOR

Mercy General Hospital

Javier Roman-Gonzalez, MD

Role: PRINCIPAL_INVESTIGATOR

Methodist Texsan Hospital

Hugh Calkins, MD

Role: PRINCIPAL_INVESTIGATOR

Johns Hopkins University

Suneet Mittal, MD

Role: PRINCIPAL_INVESTIGATOR

The Valley Hospital

Bradley Knight, MD

Role: PRINCIPAL_INVESTIGATOR

Northwestern Memorial Hospital

Anshul Patel, MD

Role: PRINCIPAL_INVESTIGATOR

Emory St Joseph's Hospital

Sung Lee, MD

Role: PRINCIPAL_INVESTIGATOR

Medstar Health Research Institute

Douglas Packer, MD

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Michael Panutich, MD

Role: PRINCIPAL_INVESTIGATOR

Hoag Memorial Hospital Presbyterian

Robert Sangrigoli, MD

Role: PRINCIPAL_INVESTIGATOR

Doylestown Hospital

Sharon Shen, MD

Role: PRINCIPAL_INVESTIGATOR

Vanderbilt Medical Center

Dhanunjaya Lakkireddy, MD

Role: PRINCIPAL_INVESTIGATOR

Kansas City Arrhythmia Research

Haseeb Jafri, MD

Role: PRINCIPAL_INVESTIGATOR

Kettering Medical Center

Timothy Mahoney, MD

Role: PRINCIPAL_INVESTIGATOR

Morristown Medical Center

Stavros Mountantonakis, MD

Role: PRINCIPAL_INVESTIGATOR

Lenox Hill Hospital

Massimo Grimaldi, MD

Role: PRINCIPAL_INVESTIGATOR

Miulli General Hospital

James Freeman, MD

Role: PRINCIPAL_INVESTIGATOR

Yale New Haven Hospital

Andy Voigt, MD

Role: PRINCIPAL_INVESTIGATOR

University of Pittsburgh Medical Center

Venkata Sagi, MD

Role: PRINCIPAL_INVESTIGATOR

Baptist Health Research Institute

Anil Bhandari, MD

Role: PRINCIPAL_INVESTIGATOR

University of Southern California

Haroon Rashid, MD

Role: PRINCIPAL_INVESTIGATOR

Inova Health Care Services

Naushad Shaik, MD

Role: PRINCIPAL_INVESTIGATOR

AdventHealth Orlando

Alan Wimmer, MD

Role: PRINCIPAL_INVESTIGATOR

St. Luke's Hospital, Kansas City, Missouri

Frank Cuoco, MD

Role: PRINCIPAL_INVESTIGATOR

Trident Medical Center

Madhu Reddy, MD

Role: PRINCIPAL_INVESTIGATOR

University of Kansas Medical Center

Ryan Aleong, MD

Role: PRINCIPAL_INVESTIGATOR

University of Colorado, Denver

Andre Gauri, MD

Role: PRINCIPAL_INVESTIGATOR

Spectrum Health System

Raul Weiss, MD

Role: PRINCIPAL_INVESTIGATOR

Ohio State University

Craig Cameron, MD

Role: PRINCIPAL_INVESTIGATOR

Oklahoma Heart

MArwan Bahu, MD

Role: PRINCIPAL_INVESTIGATOR

Phoenix Cardiovascular Research Group

Darryl Wells, MD

Role: PRINCIPAL_INVESTIGATOR

Swedish Medical Center

Ethan Ellis, MD

Role: PRINCIPAL_INVESTIGATOR

Med Center of the Rockies

Carlo Pappone, MD

Role: PRINCIPAL_INVESTIGATOR

Policlinico Di San Donato Milanese

Abdi Rasekh, MD

Role: PRINCIPAL_INVESTIGATOR

CHI Baylor St. Lukes Medical Center

Liqun Wu, MD

Role: PRINCIPAL_INVESTIGATOR

Ruijin Hospital

Chenyang Jiang, MD

Role: PRINCIPAL_INVESTIGATOR

Sir Run Run Shaw Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Phoenix Cardiovascular Research Group

Phoenix, Arizona, United States

Site Status

University of Southern California

Los Angeles, California, United States

Site Status

Hoag Memorial Hospital Presbyterian

Newport Beach, California, United States

Site Status

Mercy General Hospital

Sacramento, California, United States

Site Status

University Of Colorado Anschutz Medical Campus

Aurora, Colorado, United States

Site Status

Med Center of the Rockies

Loveland, Colorado, United States

Site Status

Yale New Haven Hospital

New Haven, Connecticut, United States

Site Status

MedStar Washington Hospital Center

Washington D.C., District of Columbia, United States

Site Status

Baptist Health Research Institute

Jacksonville, Florida, United States

Site Status

AdventHealth Orlando

Orlando, Florida, United States

Site Status

Piedmont Hospital

Atlanta, Georgia, United States

Site Status

Emory St Joseph's Hospital

Atlanta, Georgia, United States

Site Status

Northwestern Memorial Hospital

Chicago, Illinois, United States

Site Status

University of Kansas Medical Center

Kansas City, Kansas, United States

Site Status

Kansas City Arrhythmia Research

Overland Park, Kansas, United States

Site Status

The Johns Hopkins Hospital

Baltimore, Maryland, United States

Site Status

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

Spectrum Health System

Grand Rapids, Michigan, United States

Site Status

Mayo Clinic

Rochester, Minnesota, United States

Site Status

Saint Luke's Hospital of Kansas City

Kansas City, Missouri, United States

Site Status

Morristown Medical Center

Morristown, New Jersey, United States

Site Status

The Valley Hospital

Ridgewood, New Jersey, United States

Site Status

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Site Status

Lenox Hill Hospital - Northwell Health

New York, New York, United States

Site Status

The Ohio State University

Columbus, Ohio, United States

Site Status

Kettering Medical Center

Kettering, Ohio, United States

Site Status

Oklahoma Heart

Tulsa, Oklahoma, United States

Site Status

Doylestown Hospital

Doylestown, Pennsylvania, United States

Site Status

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Site Status

Trident Medical Center

Charleston, South Carolina, United States

Site Status

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status

Texas Cardiac Arrhythmia Research Foundation

Austin, Texas, United States

Site Status

CHI Baylor St. Lukes Medical Center

Houston, Texas, United States

Site Status

Baylor Scott & White The Heart Hospital - Plano

Plano, Texas, United States

Site Status

Methodist Texsan Hospital

San Antonio, Texas, United States

Site Status

Inova Health Care Services

Falls Church, Virginia, United States

Site Status

Swedish Medical Center

Seattle, Washington, United States

Site Status

Ruijin Hospital

Rui Jin Er Road, Shanghai Municipality, China

Site Status

Sir Run Run Shaw Hospital

Hangzhou, Zhejiang, China

Site Status

Policlinico Di San Donato Milanese

Milanesi, MI, Italy

Site Status

Ospedale "F. Miulli"

Bari, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States China Italy

References

Explore related publications, articles, or registry entries linked to this study.

Goyal SK, Pappone C, Grimaldi M, Lee SW, Mountantonakis S, DeVille JB, Sagi VS, Jiang CY, Jafri H, Wimmer AP, Wu LQ, Dukkipati S, Rashid H, Calkins H, Mansour M, Roman-Gonzalez J, Natale A, Ciconte G, Aryana A; STELLAR investigators. Multielectrode Radiofrequency Balloon Catheter for Paroxysmal Atrial Fibrillation: Results From the Global, Multicenter, STELLAR Study. J Cardiovasc Electrophysiol. 2025 Feb;36(2):376-386. doi: 10.1111/jce.16524. Epub 2024 Dec 16.

Reference Type DERIVED
PMID: 39686569 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BWI_2017_04

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Abbott Ventricular Tachycardia PAS
NCT05839873 ACTIVE_NOT_RECRUITING